Cambrex Corp (CBM) 43.19 $CBM Cambrex Announces
Post# of 273330
Posted On: 09/06/2016 3:04:21 PM
Cambrex Corp (CBM) 43.19 $CBM
Cambrex Announces Investment and Expansion to Large Scale, Multi-Purpose Manufacturing Capabilities at its Karlskoga, Sweden, Facility
GlobeNewswire - Tue Sep 06, 9:00AM CDT
Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced a SEK 72 million ($9 million) investment to expand large scale manufacturing capacity at its Karlskoga facility in Sweden.
CBM: 43.19 (-0.08)
Arena (ARNA) Beacon Discovery to Boost Research Platform
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:06AM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced the formation of Beacon Discovery Inc., a private drug discovery enterprise to develop compounds that can be used for drug discovery and early-stage development.
CBM: 43.19 (-0.08), ANIP: 61.30 (+1.44), ANIK: 48.21 (+0.32), ARNA: 1.56 (-0.01)
Can Cambrex (CBM) Keep the Earnings Streak Alive This Quarter?
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:09AM CDT
Cambrex (CBM) currently has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
CBM: 43.19 (-0.08)
Cambrex (CBM) is Oversold: Can It Recover?
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 8:53AM CDT
Cambrex Corporation (CBM) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
CBM: 43.19 (-0.08)
Watch for Cambrex to Potentially Rebound After Falling 2.09% Yesterday
Comtex SmarTrend(R) - Mon Aug 29, 4:00PM CDT
Cambrex (NYSE:CBM) traded in a range yesterday that spanned from a low of $43.10 to a high of $44.49. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $43.51 on volume of 347,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CBM: 43.19 (-0.08)
Cambrex to Present at Upcoming Investor Conferences in September
GlobeNewswire - Fri Aug 26, 8:40AM CDT
Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), is pleased to announce that company management will present at the following investor conferences in September:
CBM: 43.19 (-0.08)
Sanofi Diabetes Combination Drug FDA Action Date Extended
Arpita Dutt - Zacks Investment Research - Mon Aug 22, 8:29AM CDT
Sanofi (SNY) submitted updated information on the pen delivery device as part of its NDA for the fixed-ratio combination.
CBM: 43.19 (-0.08), GERN: 3.02 (+0.27), SNY: 39.43 (+0.25)
Weakness Seen in Myriad Genetics (MYGN) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 6:59AM CDT
Myriad Genetics (MYGN) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.
MYGN: 20.65 (unch), CBM: 43.19 (-0.08)
Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline
Arpita Dutt - Zacks Investment Research - Wed Aug 10, 6:38AM CDT
Considering that Repros (RPRX) has no approved product in its portfolio at the moment, investor focus will remain on pipeline updates and cash burn.
CBM: 43.19 (-0.08), GERN: 3.02 (+0.27), INCY: 83.17 (+1.15), RPRX: 1.99 (-0.01)
Arena's (ARNA) Q2 Loss Narrower, Revenues Increase Y/Y
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 6:19AM CDT
Arena (ARNA) continues to work on the advancement of its proprietary pipeline candidates.
HSKA: 55.08 (+2.59), CBM: 43.19 (-0.08), ANIP: 61.30 (+1.44), ARNA: 1.56 (-0.01)
Kite Pharma (KITE) Q2 Loss Wider but Focus is on KTE-C19
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 5:44AM CDT
Although Kite's (KITE) Q2 loss was wider-than-expected, investor focus remains primarily on the company's progress with KTE-C19.
HSKA: 55.08 (+2.59), CBM: 43.19 (-0.08), KITE: 59.98 (+1.22), AMGN: 170.87 (+1.10)
Is Cambrex Corporation (CBM) a Great Growth Stock?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:52AM CDT
One company that might be well-positioned for future earnings growth is Cambrex Corporation (CBM).
CBM: 43.19 (-0.08)
Cambrex Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Jul 28, 6:00AM CDT
- Sales increased 12% for the quarter and full year sales and profit guidance increased -
CBM: 43.19 (-0.08)
Noteworthy Friday Option Activity: CBM, OLN, FCN
DividendChannel.com - Fri Jul 22, 2:34PM CDT
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cambrex Corp , where a total volume of 2,885 contracts has been traded thus far today, a contract volume which is representative of...
CBM: 43.19 (-0.08)
Shares of CBM Up 31.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jun 21, 1:16AM CDT
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on February 10th, 2016 at $37.28. In approximately 4 months, Cambrex has returned 31.81% as of today's recent price of $49.14.
CBM: 43.19 (-0.08)
Answerthink Announces "Go Live" at Cambrex Corporation On SAP(R) ERP and LabWare LIMS 6.0 Integration Through Integrated Web Services
BusinessWire - Tue Jun 07, 8:30AM CDT
Answerthink, a division of The Hackett Group, Inc.. (NASDAQ: HCKT) and a premier developer, provider and supporter of solutions based on SAP(R) software, today announced the successful implementation of a laboratory information management system (LIMS) solution at Cambrex Corporation's Sweden facility.
CBM: 43.19 (-0.08), HCKT: 16.72 (+0.09)
Cambrex Has Returned 35.9% Since SmarTrend Recommendation (CBM)
Comtex SmarTrend(R) - Fri Jun 03, 1:09PM CDT
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on February 10th, 2016 at $37.28. In approximately 4 months, Cambrex has returned 35.94% as of today's recent price of $50.68.
CBM: 43.19 (-0.08)
Cambrex to Present at the Jefferies 2016 Global Healthcare Conference
GlobeNewswire - Fri Jun 03, 10:00AM CDT
Cambrex Corporation (NYSE:CBM) ("Cambrex"
is pleased to announce that Steven Klosk, President and Chief Executive Officer, will present at the Jefferies 2016 Global Healthcare Conference on June 10, 2016 at 10:00 a.m. EDT in New York City.
CBM: 43.19 (-0.08)
Cambrex Announces Closing of New $500 Million Senior Credit Facility
GlobeNewswire - Mon May 23, 5:45AM CDT
Cambrex Corporation (NYSE:CBM) ("Cambrex" is pleased to announce that the Company has closed a new $500 million senior secured revolving credit facility (the "Credit Facility", replacing the previous $250 million facility.
CBM: 43.19 (-0.08)
Cambrex Announces Investment and Expansion to Large Scale, Multi-Purpose Manufacturing Capabilities at its Karlskoga, Sweden, Facility
GlobeNewswire - Tue Sep 06, 9:00AM CDT
Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced a SEK 72 million ($9 million) investment to expand large scale manufacturing capacity at its Karlskoga facility in Sweden.
CBM: 43.19 (-0.08)
Arena (ARNA) Beacon Discovery to Boost Research Platform
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:06AM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced the formation of Beacon Discovery Inc., a private drug discovery enterprise to develop compounds that can be used for drug discovery and early-stage development.
CBM: 43.19 (-0.08), ANIP: 61.30 (+1.44), ANIK: 48.21 (+0.32), ARNA: 1.56 (-0.01)
Can Cambrex (CBM) Keep the Earnings Streak Alive This Quarter?
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:09AM CDT
Cambrex (CBM) currently has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
CBM: 43.19 (-0.08)
Cambrex (CBM) is Oversold: Can It Recover?
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 8:53AM CDT
Cambrex Corporation (CBM) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
CBM: 43.19 (-0.08)
Watch for Cambrex to Potentially Rebound After Falling 2.09% Yesterday
Comtex SmarTrend(R) - Mon Aug 29, 4:00PM CDT
Cambrex (NYSE:CBM) traded in a range yesterday that spanned from a low of $43.10 to a high of $44.49. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $43.51 on volume of 347,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CBM: 43.19 (-0.08)
Cambrex to Present at Upcoming Investor Conferences in September
GlobeNewswire - Fri Aug 26, 8:40AM CDT
Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), is pleased to announce that company management will present at the following investor conferences in September:
CBM: 43.19 (-0.08)
Sanofi Diabetes Combination Drug FDA Action Date Extended
Arpita Dutt - Zacks Investment Research - Mon Aug 22, 8:29AM CDT
Sanofi (SNY) submitted updated information on the pen delivery device as part of its NDA for the fixed-ratio combination.
CBM: 43.19 (-0.08), GERN: 3.02 (+0.27), SNY: 39.43 (+0.25)
Weakness Seen in Myriad Genetics (MYGN) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 6:59AM CDT
Myriad Genetics (MYGN) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.
MYGN: 20.65 (unch), CBM: 43.19 (-0.08)
Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline
Arpita Dutt - Zacks Investment Research - Wed Aug 10, 6:38AM CDT
Considering that Repros (RPRX) has no approved product in its portfolio at the moment, investor focus will remain on pipeline updates and cash burn.
CBM: 43.19 (-0.08), GERN: 3.02 (+0.27), INCY: 83.17 (+1.15), RPRX: 1.99 (-0.01)
Arena's (ARNA) Q2 Loss Narrower, Revenues Increase Y/Y
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 6:19AM CDT
Arena (ARNA) continues to work on the advancement of its proprietary pipeline candidates.
HSKA: 55.08 (+2.59), CBM: 43.19 (-0.08), ANIP: 61.30 (+1.44), ARNA: 1.56 (-0.01)
Kite Pharma (KITE) Q2 Loss Wider but Focus is on KTE-C19
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 5:44AM CDT
Although Kite's (KITE) Q2 loss was wider-than-expected, investor focus remains primarily on the company's progress with KTE-C19.
HSKA: 55.08 (+2.59), CBM: 43.19 (-0.08), KITE: 59.98 (+1.22), AMGN: 170.87 (+1.10)
Is Cambrex Corporation (CBM) a Great Growth Stock?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:52AM CDT
One company that might be well-positioned for future earnings growth is Cambrex Corporation (CBM).
CBM: 43.19 (-0.08)
Cambrex Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Jul 28, 6:00AM CDT
- Sales increased 12% for the quarter and full year sales and profit guidance increased -
CBM: 43.19 (-0.08)
Noteworthy Friday Option Activity: CBM, OLN, FCN
DividendChannel.com - Fri Jul 22, 2:34PM CDT
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cambrex Corp , where a total volume of 2,885 contracts has been traded thus far today, a contract volume which is representative of...
CBM: 43.19 (-0.08)
Shares of CBM Up 31.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jun 21, 1:16AM CDT
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on February 10th, 2016 at $37.28. In approximately 4 months, Cambrex has returned 31.81% as of today's recent price of $49.14.
CBM: 43.19 (-0.08)
Answerthink Announces "Go Live" at Cambrex Corporation On SAP(R) ERP and LabWare LIMS 6.0 Integration Through Integrated Web Services
BusinessWire - Tue Jun 07, 8:30AM CDT
Answerthink, a division of The Hackett Group, Inc.. (NASDAQ: HCKT) and a premier developer, provider and supporter of solutions based on SAP(R) software, today announced the successful implementation of a laboratory information management system (LIMS) solution at Cambrex Corporation's Sweden facility.
CBM: 43.19 (-0.08), HCKT: 16.72 (+0.09)
Cambrex Has Returned 35.9% Since SmarTrend Recommendation (CBM)
Comtex SmarTrend(R) - Fri Jun 03, 1:09PM CDT
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on February 10th, 2016 at $37.28. In approximately 4 months, Cambrex has returned 35.94% as of today's recent price of $50.68.
CBM: 43.19 (-0.08)
Cambrex to Present at the Jefferies 2016 Global Healthcare Conference
GlobeNewswire - Fri Jun 03, 10:00AM CDT
Cambrex Corporation (NYSE:CBM) ("Cambrex"
is pleased to announce that Steven Klosk, President and Chief Executive Officer, will present at the Jefferies 2016 Global Healthcare Conference on June 10, 2016 at 10:00 a.m. EDT in New York City. CBM: 43.19 (-0.08)
Cambrex Announces Closing of New $500 Million Senior Credit Facility
GlobeNewswire - Mon May 23, 5:45AM CDT
Cambrex Corporation (NYSE:CBM) ("Cambrex"
is pleased to announce that the Company has closed a new $500 million senior secured revolving credit facility (the "Credit Facility", replacing the previous $250 million facility. CBM: 43.19 (-0.08)
(0)
(0)